DocGo Announces Fourth Quarter and Full-Year 2022 Results

DocGo Inc. (Nasdaq: DCGO), a leading provider of last-mile mobile health services, today announced financial and operating results for the fourth quarter and full-year ended December 31, 2022.

Full Year 2022 Financial Highlights

• Full-year 2022 revenue increased to $440.5 million, compared to $318.7 million for the full-year 2021, an increase of 38%.
• Gross Margin for 2022 was 35% compared to 34% in 2021.
• Mobile Health revenue was approximately $325.9 million in 2022, compared to $234.4 million in 2021, an increase of 39%.
• Medical transport revenue was approximately $114.6 million in 2022, compared to $84.3 million in 2021, an increase of 36%.
• Full-year net income amounted to $30.7 million, compared to net income of $19.2 million for the full-year 2021, an increase of 60%.
• Full-year 2022 Adjusted EBITDA² was $41.3 million, compared to $25.1 million for the full-year 2021, an increase of 65%.
• As of December 31, 2022, the company held total cash and cash equivalents, including restricted cash, of $164.1 million.

Fourth Quarter 2022 Financial Highlights

• Total Q4 2022 revenue was $108.8 million, which includes approximately $1 million of COVID testing revenue, compared to $121.3 million in Q4 2021, which includes approximately $50 million of non-recurring COVID testing revenue.
• Mobile Health revenue was $71.8 million, which includes approximately $1 million of COVID testing revenue, compared to $102.6 million for the fourth quarter of 2021, which includes approximately $50 million of COVID testing revenue.
• Transportation Services revenue was $37 million compared to $18.7 million for the fourth quarter of 2021, an increase of 98%.
• Net income was $7.1 million for the fourth quarter of 2022, compared to $20.3 million for the fourth quarter of 2021. Net income in the fourth quarter of 2021 was positively impacted by approximately $50 million of non-recurring mass COVID testing revenue, compared to $1 million in Q4 2022.
• Adjusted EBITDA² was $6.8 million for the fourth quarter of 2022 compared to $17.3 million for the fourth quarter of 2022. Adjusted EBITDA in the fourth quarter of 2021 was positively impacted by approximately $50 million of non-recurring mass COVID testing revenue and Adjusted EBITDA in the fourth quarter of 2022 was negatively impacted by startup costs associated with onboarding numerous new contracts.

2023 Guidance

The company sees continued strong demand from its customers for both mobile health and transportation services solutions and anticipates 2023 revenue to be approximately $500-$510 million, representing growth of approximately 14% to 16% over 2022 on an as-reported basis, or growth of 36% to 40% if non-recurring mass Covid testing revenue of approximately $75 million in 2022 is excluded. Adjusted EBITDA³ is anticipated to be approximately $45-$50 million. Full-year gross margin is expected to be approximately 35%.

Select Corporate Highlights

• Entered into a partnership with Redirect Health, a platform that creates and manages healthcare solutions for businesses and employees nationwide, to provide on-demand, urgent mobile care to patients in New Jersey and New York. Through Redirect Health’s referral team, DocGo’s high quality, on-demand mobile health services are now available to thousands of Redirect Health’s members residing in those states.
• Announced the appointment of veteran human resources executive Vina Leite, MS, to its Board of Directors.
• Awarded a new Rapid Falls Response Service contract in the U.K., via its U.K. subsidiary, Ambulnz Community Partners, potentially helping elderly patients recover from falls without requiring a trip to the emergency room and establishing clinical pathways to help prevent future incidents.
• Launched an app integrated with the EPIC Health Information Technology platform which allows clinical staff to order DocGo’s medical transport services and/or mobile health visits from within the EPIC system.
• Secured a $90 million line of credit with Citibank, N.A. The line includes a $50 million accordion option and carries a five year term which remains unused as of today.
• DocGo’s current Backlog⁴ is $180 million over three years, of which all related contracts are expected to be fully rolled out by the end of Q3 2023.
• DocGo currently has 34 active RFPs pending award, totaling over $1 billion in aggregate contract value. None of these RFPs are included in our current guidance as any award to DocGo is not guaranteed.

Anthony Capone, Chief Executive Officer of DocGo, commented, “DocGo began 2022 with revenue guidance of $400 million - $420 million and we closed the year at $440.5 million. We meticulously replaced non-recurring mass COVID testing revenue with new contracts and programs, both in the U.S. and U.K. In 2023, we are highly focused on our new ‘rapid normalization initiative’ which seeks to reduce the time and costs associated with onboarding new contracts, which historically has ranged from 90 to 120 days, down to 60 days. Additionally, we have already created a backlog of more than $180 million of new contract awards. Overall, I am extremely pleased with our performance both during the fourth quarter and full-year, and I am very confident about what we can achieve this year and beyond.”

Norm Rosenberg, Chief Financial Officer of DocGo, added, "During the year, the company experienced substantial costs associated with the launch of numerous new projects. These costs included estimated incremental costs of approximately $12 million from the usage of subcontracted agency labor, $3 million from rental vehicle fees and $14 million from overtime rates, all in excess of the expected steady-state expense levels. We estimate that collectively, this created a negative gross margin impact of more than 600 basis points in 2022. Fortunately, all of these costs are a byproduct of our substantial growth, and we expect our rapid normalization initiative to significantly mitigate these costs over time."

Conference call and webcast

DocGo management will host a conference call and webcast to discuss the fourth quarter results today, March 13^th at 5:00 pm ET. To access the conference call, please dial 1-877-407-0784 (U.S.) or 1-201-689-8560 (international). Reference conference ID 13736245.

To access the Call me™ option, which avoids having to wait for an operator, click here.

The webcast can be accessed at: https://viavid.webcasts.com/starthere.jsp?ei=1596989&tp_key=4882d58a60 or under “Events” on the “Investors” section of the Company’s website, https://ir.docgo.com/.

A replay of the webcast will be archived on the Company’s investor relations page through March 20th, 2023 at approximately 5:00 pm ET.

About DocGo

DocGo is a leading provider of last-mile mobile health services. DocGo is disrupting the traditional four-wall healthcare system by providing care to patients where and when they need it. DocGo's innovative technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.

Forward-Looking Statements

This announcement contains forward-looking statements (including within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and Section 27A of the U.S. Securities Act of 1933, as amended) concerning DocGo. These statements include, but are not limited to, statements that address our expected future business and financial performance and statements about (i) our plans, objectives and intentions with respect to future operations, services and products, including our transition to non-COVID related services, geographic expansion, normalization initiative, new and existing contracts, M&A activity, workforce growth, leadership transition, cash position and share repurchase program, (ii) our competitive position and opportunities, including our ability to realize the benefits from our operating model, and (iii) other statements identified by words such as "may", "will", "expect", "intend", "plan", "potential", "believe", "seek", "could", "estimate", "judgment", "targeting", "should", "anticipate", "predict" "project", "aim", "goal", "outlook", "guidance", and similar words, phrases or expressions. These forward-looking statements are based on management's current expectations and beliefs, as well as assumptions made by, and information currently available to, management, and current market trends and conditions. Forward-looking statements inherently involve risks and uncertainties, many of which are beyond our control, and which may cause actual results to differ materially from those contained in our forward-looking statements. Accordingly, you should not place undue reliance on such statements. Particular uncertainties that could materially affect current or future results include possible accounting adjustments made in the process of finalizing reported financial results; any risks associated with global economic conditions and concerns; the effects of global outbreaks of pandemics or contagious diseases or fear of such outbreaks, such as the COVID-19 coronavirus pandemic; competitive pressures; pricing declines; rates of growth in our target markets; our ability to improve gross margins; cost-containment measures; legislative and regulatory actions; the impact of legal proceedings and compliance risks; the impact on our business and reputation in the event of information technology system failures, network disruptions, cyber-attacks, or losses or unauthorized access to, or release of, confidential information; and the ability of the company to comply with laws and regulations regarding data privacy and protection. We undertake no intent or obligation to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events or otherwise.

Non-GAAP Financial Measures

The following information provides definition and reconciliation of the non-GAAP financial measure presented in this earnings release to the most directly comparable financial measure calculated and presented in accordance with generally accepted accounting principles (GAAP). The company has provided this non-GAAP financial information, which is not calculated or presented in accordance with GAAP, as information supplemental and in addition to the financial measures presented in this earnings release that are calculated and presented in accordance with GAAP. Such non-GAAP financial measure should not be considered superior to, as a substitute for or alternative to, and should be considered in conjunction with, the GAAP financial measures presented in this earnings release. The non-GAAP financial measure in this earnings release may differ from similarly titled measures used by other companies.

Adjusted EBITDA

Adjusted EBITDA is considered a non-GAAP financial measure under the Securities and Exchange Commission’s (“SEC”) rules because it excludes certain amounts included in net income (loss) calculated in accordance with GAAP. Specifically, Adjusted EBITDA is arrived at by taking reported GAAP Net Income and adding back the following items: net interest expense/ (income), Provision/(benefit) for income taxes, depreciation and amortization, other (income)/expense, non-cash equity-based compensation and certain other non-recurring expenses consisting of expenses incurred in relation to the Company’s merger with Motion in 2021, certain one-time legal settlements and certain one-time expenses incurred in connection with acquisitions, beyond those that are typically incurred.

The Company’s management believes that its Adjusted EBITDA measure is useful in evaluating DocGo’s operating performance, as the calculation of this measure generally eliminates the effect of financing and income taxes and the accounting effects of capital spending and acquisitions, as well as other items of a non-recurring and/or non-cash nature. Adjusted EBITDA is not intended to be a measure of GAAP cash flow, as this measure does not consider certain cash-based expenses, such as payments for taxes or debt service. Management believes that using Adjusted EBITDA in conjunction with GAAP measures such as net income assists investors in getting a more complete picture of the Company’s financial results and operations, affording them with a more complete view of what management considers to be the Company’s core operating performance as well as offering the ability to assess such performance as compared with that of prior periods and management’s public guidance. While many companies use Adjusted EBITDA as a performance measure, not all companies use identical calculations for determining Adjusted EBITDA. As such, DocGo’s presentation of Adjusted EBITDA might not be comparable to similarly titled measures of other companies.

The table below reflects the reconciliation of Net Income (Loss) to Adjusted EBITDA for the three and twelve months ended December 31, 2022 compared to the same periods in 2021 (in millions):

View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005664/en/